Home | Adhd | Know The FDA Approved Biosimilar Drugs For Adult ADHD

Know The FDA Approved Biosimilar Drugs For Adult ADHD

Attention deficit hyperactivity disorder or ADHD interferes with the functioning and development of the brain. The disorder affects people of any age group, and the symptoms of ADHD can be easily recognized. Adults who are diagnosed with the disease turn out to be a victim of the disorder since childhood. FDA has approved some biosimilar drugs for adult ADHD as the disorder takes a severe form in the case of adults.

Know The FDA Approved Biosimilar Drugs For Adult ADHD

Why is a diagnosis required?

In many cases, the symptoms of ADHD in children are often ignored. If the symptoms persist for extended periods, the child may have ADHD and it becomes crucial for a diagnosis. Children usually face problems to pay attention while completing a certain task, or difficulty in controlling the behavior, or they easily get involved in an intense activity. Such problems cause significant damage to the academic, social, and personal lives of the ones affected.

Biosimilar drugs for ADHD

The symptoms of ADHD can be treated with medications and therapies. Several biosimilar drugs for adult ADHD that are approved by FDA are available to treat the symptoms of ADHD. Some of these are:

  • FDA has approved the use of the generic drug Strattera (atomoxetine) to treat the condition of ADHD in pediatric and adult patients. The manufacturers have gained the permission of manufacturing the drug in multiple strengths. Atomoxetine must be dispensed with a patient medication guide that describes the uses and warnings of the drug.
  • Shire’s drug Mydayis (SHP465) has also received FDA’s approval to treat patients aged above 12 years, who suffer from ADHD. The drug contains two vital active ingredients—amphetamine and dextroamphetamine that help treat children suffering from hyperactiveness and impulsivity, which are the two major symptoms of ADHD. The therapy is formulated to stay up to 16 hours in the body.
  • Cotempla XR-ODT also received FDA approval to treat patients aged between 6 and 17 years. It is the first and only orally disintegrating tablet that dissolves in the patient’s mouth. Hence, this need not be chewed or dissolved in water, unlike other tablets or drugs.

These adult ADHD biosimilar drugs treat the conditions of the disorder slowly, and it is advised to seek a doctor before taking these medications.

Disclaimer:
The content provided on our blog site traverses numerous categories, offering readers valuable and practical information. Readers can use the editorial team’s research and data to gain more insights into their topics of interest. However, they are requested not to treat the articles as conclusive. The website team cannot be held responsible for differences in data or inaccuracies found across other platforms. Please also note that the site might also miss out on various schemes and offers available that the readers may find more beneficial than the ones we cover.

Latest Articles